During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk multiple myeloma (MM)?

In this podcast, Sonneveld discusses trial results presented during EHA2021 on the efficacy of novel treatments for patients with high-risk MM, a patient group associated with poor outcomes and shorter remission rates. He believes that identifying high-risk patients and selecting them for more intensive targeted maintenance treatment could be crucial in preventing relapse.

Hosted on Acast. See acast.com/privacy for more information.